MX2023002093A - Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40). - Google Patents
Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40).Info
- Publication number
- MX2023002093A MX2023002093A MX2023002093A MX2023002093A MX2023002093A MX 2023002093 A MX2023002093 A MX 2023002093A MX 2023002093 A MX2023002093 A MX 2023002093A MX 2023002093 A MX2023002093 A MX 2023002093A MX 2023002093 A MX2023002093 A MX 2023002093A
- Authority
- MX
- Mexico
- Prior art keywords
- antibody
- treating
- autoimmune disease
- antagonistic
- antigen binding
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 208000023275 Autoimmune disease Diseases 0.000 title abstract 2
- 230000003042 antagnostic effect Effects 0.000 title 1
- 239000000427 antigen Substances 0.000 abstract 2
- 102000036639 antigens Human genes 0.000 abstract 2
- 108091007433 antigens Proteins 0.000 abstract 2
- 108010029697 CD40 Ligand Proteins 0.000 abstract 1
- 229940123189 CD40 agonist Drugs 0.000 abstract 1
- 101150013553 CD40 gene Proteins 0.000 abstract 1
- 102100032937 CD40 ligand Human genes 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 102000009109 Fc receptors Human genes 0.000 abstract 1
- 108010087819 Fc receptors Proteins 0.000 abstract 1
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 abstract 1
- 102000009490 IgG Receptors Human genes 0.000 abstract 1
- 108010073807 IgG Receptors Proteins 0.000 abstract 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 abstract 1
- 102100040245 Tumor necrosis factor receptor superfamily member 5 Human genes 0.000 abstract 1
- 230000004913 activation Effects 0.000 abstract 1
- 230000008485 antagonism Effects 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 abstract 1
- 238000004132 cross linking Methods 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000001727 in vivo Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 230000035772 mutation Effects 0.000 abstract 1
- 230000011664 signaling Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/71—Decreased effector function due to an Fc-modification
Landscapes
- Health & Medical Sciences (AREA)
- Immunology (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
Se proporciona un método para tratar una enfermedad autoinmune como el Síndrome de Sjögren. El método comprende la administración de un anticuerpo o una porción del mismo que se une a un antígeno que se une específicamente a un epítopo de CD40 asociado con el antagonismo. El anticuerpo o la porción de unión al antígeno del mismo no exhibe actividad agonista de CD40 en pruebas preclínicas in vitro o in vivo. El anticuerpo inhibe la señalización inducida por CD40L en las DCs, lo que da como resultado, al menos en parte, una producción reducida de citocinas proinflamatorias y una reducción de los marcadores de activación de la superficie celular, CD86 y CD54. Los anticuerpos pueden comprender una región Fc que contiene una mutación que reduce o elimina la unión a los receptores Fc, reduciendo o eliminando la reticulación o la agrupación mediada por el receptor Fc gamma (Fc?R).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063070209P | 2020-08-25 | 2020-08-25 | |
| PCT/US2021/047610 WO2022046942A1 (en) | 2020-08-25 | 2021-08-25 | Method of treating an autoimmune disease with antagonistic cd40 monoclonal antibodies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023002093A true MX2023002093A (es) | 2023-03-15 |
Family
ID=77693641
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023002093A MX2023002093A (es) | 2020-08-25 | 2021-08-25 | Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40). |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20230331860A1 (es) |
| EP (1) | EP4204099A1 (es) |
| JP (1) | JP2023539736A (es) |
| KR (1) | KR20230054451A (es) |
| CN (1) | CN116322761A (es) |
| AU (1) | AU2021331087A1 (es) |
| BR (1) | BR112023002803A2 (es) |
| CA (1) | CA3190727A1 (es) |
| IL (1) | IL300765A (es) |
| MX (1) | MX2023002093A (es) |
| WO (1) | WO2022046942A1 (es) |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| KR20200074993A (ko) * | 2017-11-03 | 2020-06-25 | 노파르티스 아게 | 쇼그렌 증후군 치료에 사용하기 위한 항-cd40 항체 |
| AR117091A1 (es) * | 2018-11-19 | 2021-07-07 | Bristol Myers Squibb Co | Anticuerpos monoclonales antagonistas contra cd40 y sus usos |
-
2021
- 2021-08-25 AU AU2021331087A patent/AU2021331087A1/en active Pending
- 2021-08-25 KR KR1020237009804A patent/KR20230054451A/ko unknown
- 2021-08-25 JP JP2023513407A patent/JP2023539736A/ja active Pending
- 2021-08-25 IL IL300765A patent/IL300765A/en unknown
- 2021-08-25 US US18/042,553 patent/US20230331860A1/en active Pending
- 2021-08-25 MX MX2023002093A patent/MX2023002093A/es unknown
- 2021-08-25 BR BR112023002803A patent/BR112023002803A2/pt unknown
- 2021-08-25 CA CA3190727A patent/CA3190727A1/en active Pending
- 2021-08-25 EP EP21766803.7A patent/EP4204099A1/en active Pending
- 2021-08-25 CN CN202180052235.3A patent/CN116322761A/zh active Pending
- 2021-08-25 WO PCT/US2021/047610 patent/WO2022046942A1/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2022046942A1 (en) | 2022-03-03 |
| CN116322761A (zh) | 2023-06-23 |
| AU2021331087A1 (en) | 2023-04-20 |
| KR20230054451A (ko) | 2023-04-24 |
| EP4204099A1 (en) | 2023-07-05 |
| IL300765A (en) | 2023-04-01 |
| CA3190727A1 (en) | 2022-03-03 |
| JP2023539736A (ja) | 2023-09-19 |
| US20230331860A1 (en) | 2023-10-19 |
| BR112023002803A2 (pt) | 2023-03-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Wirths et al. | ABCB1 transporter discriminates human resting naive B cells from cycling transitional and memory B cells | |
| Charpin et al. | Immunohistochemical detection of laminin in 98 human breast carcinomas: a light and electron microscopic study | |
| Meuer et al. | Identification of the receptor for antigen and major histocompatibility complex on human inducer T lymphocytes | |
| Vaillant et al. | Jekyll or Hyde: does Matrigel provide a more or less physiological environment in mammary repopulating assays? | |
| Truchetet et al. | Prostaglandin I2 analogues enhance already exuberant Th17 cell responses in systemic sclerosis | |
| Schmaler et al. | IL-7R signaling in regulatory T cells maintains peripheral and allograft tolerance in mice | |
| Hartgring et al. | Interleukin-7-aggravated joint inflammation and tissue destruction in collagen-induced arthritis is associated with T-cell and B-cell activation | |
| JP2018524987A5 (es) | ||
| Lauder et al. | Enhanced antitumor immunity through sequential targeting of PI3Kδ and LAG3 | |
| MX2022008582A (es) | Anticuerpos anti-trem2 y metodos para utilizarlos. | |
| MX2021005565A (es) | Anticuerpos monoclonales antagonistas contra cumulo de diferenciacion 40 (cd40) y sus usos. | |
| Ribeiro et al. | Intermediate expression of CCRL1 reveals novel subpopulations of medullary thymic epithelial cells that emerge in the postnatal thymus | |
| BR112021021996A2 (pt) | Métodos para administração de imunoterapia com receptores de antígeno quimérico | |
| MX2023002093A (es) | Metodo de tratamiento de una enfermedad autoinmune con anticuerpos monoclonales antagonistas para el cumulo de diferenciacion 40 (cd40). | |
| Gao et al. | An essential role for constitutive Schiff base-forming ligands in antigen presentation to murine T cell clones. | |
| Lader et al. | Generation of human osteoclasts in stromal cell‐free and stromal cell‐rich cultures: Differences in osteoclast CD11c/CD18 integrin expression | |
| Nicoud et al. | Impact of histamine H4 receptor deficiency on the modulation of T cells in a murine breast cancer model | |
| Gunduz et al. | T cell subpopulations and IL‐2R in vitiligo | |
| Yao et al. | Langerhans cells transfer targeted antigen to dermal DC and acquire MHC-II in vivo | |
| Yanagawa et al. | Enhancement of stromal cell‐derived factor‐1α‐induced chemotaxis for CD4/8 double‐positive thymocytes by fibronectin and laminin in mice | |
| Lepesant et al. | Mouse thymic epithelial cell lines interact with and select a CD3lowCD4+ CD8+ thymocyte subset through an LFA-1-dependent adhesion-de-adhesion mechanism | |
| WARZOCHA et al. | PROGNOSTIC SIGNIFICANCE OF TNF AND ITS p55 SOLUBLE RECEPTOR IN MALIGNANT LYMPHOMAS. | |
| Lim et al. | China’s demographic outlook | |
| Schallhammer et al. | Phenotypic comparison of natural killer cells from peripheral blood and from early pregnancy decidua. | |
| Rivas et al. | Functional and phenotypic analysis of in vitro stimulated canine peripheral blood mononuclear cells |